Crestor on track for action in mid-2002
Executive Summary
AstraZeneca submits NDA for Crestor (rosuvastatin) to FDA June 26. The company expects a standard review for the cholesterol-lowering agent. A decision on whether to sign up a co-promotion partner is expected shortly (1"The Pink Sheet" June 18, p. 10)